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Abstract
Background: Previous studies have investigated the sustained aberrantly activated Interleukin-6 (IL-6)/signal
transducer and activator of transcription 3 (STAT3) signaling pathway is crucial for pancreatic cancer growth and
metastasis. Suppressor of cytokine signaling 3 (SOCS3), as a key negative feedback regulator of this signaling
pathway, is usually down-regulated in various cancers. In the present study, we aim at exploring the biological
function and the underlying molecular regulation mechanisms of SOCS3 in pancreatic cancer.
Methods: The expression of SOCS3 and other genes in pancreatic cancer was examined by Quantitative real-time
PCR, western blotting and immunohistochemical staining. The interaction between pSTAT3 and DNA Methyltransferase
1 (DNMT1) was investigated by co-immunoprecipitation assay. Luciferase reporter assay was used to investigate the
transcriptional regulation of pSTAT3 and DNMT1 on the SOCS3 gene. The effects of SOCS3 on the biological behavior
of pancreatic cancer cells were assessed both in vitro and vivo. Furthermore, we performed a comprehensive analysis
of the expression of SOCS3 in a pancreatic cancer tissue microarray (TMA) and correlated our findings with
pathological parameters and outcomes of the patients.
Results: We showed that SOCS3 expression was decreased in phosphorylated STAT3 (pSTAT3)-positive tumors
and was negatively correlated with pSTAT3 in pancreatic cancer cells. We also found that IL-6/STAT3 promoted
SOCS3 promoter hypermethylation by increasing DNMT1 activity; silencing DNMT1 or 5-aza-2-deoxycytidine
(5-AZA) treatment could reverse the down-regulation of SOCS3 mediated by IL-6. Using co-immunoprecipitation
and luciferase reporter assays, we found that STAT3 recruited DNMT1 to the promoter region of SOCS3 and
inhibited its transcriptional activity. Overexpression of SOCS3 significantly inhibited cell proliferation, which may
be due to the increase in G1-S phase arrest; overexpression of SOCS3 also inhibited cell migration and invasion as
well as tumorigenicity in nude mice. Pancreatic cancer tissue microarray analysis showed that high SOCS3
expression was a good prognostic factor and negatively correlated with tumor volume and metastasis.
Conclusion: We demonstrated that activated IL-6/STAT3 signaling could induce SOCS3 methylation via DNMT1,
which led to pancreatic cancer growth and metastasis. These data also provided a mechanistic link between
sustained aberrantly activated IL-6/STAT3 signaling and SOCS3 down-regulation in pancreatic cancer. Thus,
inhibitors of STAT3 or DNMT1 may become novel strategies for treating pancreatic cancer.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is currently
one of the deadliest solid tumors, with a median survival
duration of approximately 6 months following diagnosis
and a five-year survival rate of less than 5 % [1]. PDAC
has very few early symptoms and develops rapidly; thus,
most carcinomas are confirmed in an advanced stage
and are not treatable by surgery [2]. The dense desmo-
plastic stroma of PDAC contains activated fibroblasts,
inflammatory cells, various inflammatory cytokines and
growth factors that lead to an inflammatory microenvir-
onment that provides survival and proliferative signals
to promote tumor initiation, progression and treatment
resistance [3, 4]. Thus, despite exciting recent progress
in biological target therapy for tumors, most targeted
therapies show no clinical benefit in PDAC [5].
Chronic inflammation is an important risk factor for
cancer development at many sites [6]. The inflammatory
microenvironment exposures induce epigenetic modifi-
cations by DNMTs, altering the expression of tumor
suppressor genes, which promotes PDAC tumorigenesis
and progression [7, 8]. As an important member of the
tumor inflammatory microenvironment, the pro-
inflammatory cytokine IL-6 is involved in pancreatic
cancer development [9, 10] and directly affects cancer
cell growth and survival through activation of STAT3
[11–13]. The activated pSTAT3 functions as nuclear
transcription factor regulating genes involved in tumor
proliferation, survival, angiogenesis and invasion [14].
SOCS family is cytokine-inducible negative regulators of
this cytokine signaling. As a member of the family,
SOCS3 can be induced by IL-6/STAT3 signal axis and
plays an important role in preventing excessive activa-
tion of the signaling pathway. SOCS3 blocks the phos-
phorylation of STAT3 by inhibiting Jak-2 directly [15].
The function of SOCS3 in cancer remains controversial
as SOCS3 has been shown to possess both tumor limit-
ing and tumor promoting properties. SOCS3 was re-
ported to function as a tumor suppressor in breast
cancer [16], hepatocellular cancer [17], small cell lung
cancer [18], prostate cancer [19] and so on. However,
other studies demonstrated that it enhanced tumor ag-
gressiveness and associated with poor outcomes in renal
cell carcinoma [20], T-cell lymphoma [21]. Few studies
are available on evaluating SOCS3 expression in associ-
ation to tumor biological behavior and prognosis specif-
ically in PDAC. The aim of this study is to explore the
potential roles of SOCS3 in PDAC.
The epigenetic gene silencing of SOCS3 due to pro-
moter methylation is observed in many malignancies, in-
cluding head-neck cancer [22], cervical cancer [23],
pancreatic cancer [24] and hepatocellular cancer [24].
Multiple studies have demonstrated that IL-6 could pro-
mote tumourigenesis and progression by activating
DNMT1, inducing aberrant DNA methylation of tumor
suppressor genes and silencing their expression [24–26].
Moreover, previous studies have suggested that the IL-6/
STAT3 signaling pathway is aberrantly activated in pan-
creatic cancer and the molecular mechanism remains
unknown [27]. We thus hypothesized that the expression
of SOCS3 was epigenetically silenced in pancreatic can-
cers owing to IL-6 induced DNMT1 expression.
In this study, for the first time, we demonstrate that
activated IL-6/STAT3 signaling induced SOCS3 methy-
lation via DNMT1, which may promote pancreatic can-
cer growth and metastasis both in vitro and vivo. We
also provide a mechanistic link between sustained aber-
rantly activated IL-6/STAT3 signaling and SOCS3 down-
regulation in pancreatic cancer.
Methods
Tissue samples, cell lines and reagents
Five pairs of primary pancreatic cancer and pericancer-
ous tissues were obtained from Shanghai First People’s
Hospital. All participants provided informed consent ac-
cording to the Helsinki Declaration, and the protocol for
the present study was approved by the Ethics Committee
of Shanghai First People’s Hospital (Shanghai, China).
The tissues were frozen at −80°C until use or fixed in
formalin. Nine pancreatic cancer cell lines, Aspc1,
Bxpc3, Capan1, Capan2, Cfpac, Hpaf, Panc1, Sw1990,
Hs766T were cultured in RPMI 1640 or DMEM supple-
mented with 10 % fetal bovine serum. Human recombin-
ant IL-6 and STAT3 inhibitor S31-201 were purchased
from Sino Biological Inc. (Beijing, China) and Selleck-
chem (Houston, Texas, USA), respectively. 5-AZA was
purchased from Sigma (St. Louis, MO, USA).
Immunohistochemistry
Sections of 5μm from formalin-fixed and paraffin-
embedded specimens were deparaffinized using xylene
and rehydrated in graded ethanol. Samples were then
preincubated with 3 % H2O2 to inhibit endogenous per-
oxides activity. Sections were incubated at 4°C overnight
with primary antibodies against pSTAT3(1:100; CST),
DNMT1(1:100; CST), DNMT3a(1:100; Santa Cruz), IL-
6(1:50; Santa Cruz), SOCS3(1:50; Santa Cruz), and then
with HRP-labeled secondary antibodies (MaxVision,
China) at room temperature for 15 min, and freshly
prepared 3,3′-diaminobenzidine (DAB) for color develop-
ment for 5 min. In the controls, the primary antibody was
replaced with phosphate-buffered saline. The evaluation of
the immunohistochemical staining was performed inde-
pendently by two authors without knowledge of the clinic-
pothological information. The intensity of immunostaining
(0 = negative, 1 = weak, 2 =moderate, and 3 = intense) and
the percentage of positive cells (0 % = negative, 1 %–25 %–
1, 26 %–50 %–2, 51 %–75 % = 3, ≥76 % = 4) were assessed.
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The two scores were multiplied to give a final score and
the immunohistochemical stainings were finally deter-
mined as negative: score 0; low expression: score ≤4; mod-
erate expression: score 5–8; high expression: score 9–12.
Protein extraction and Western blot analyses
Cells were lysed in a buffer solution containing 2 × SDS,
1 % phosphatase inhibitor and 1 % protease inhibitor.
The protein concentration of the cell lysates was mea-
sured using the Pierce BCA Protein Assay Kit. Approxi-
mately 30 μg of protein from each sample was separated
on 8 %–12 % SDS-PAGE and transferred to a PVDF
membrane. The membrane was incubated in blocking
buffer for 1 h at room temperature. The blocking buffer
consisted of 5 % non-fat dry milk in Tris buffered saline
containing 0.1 % Tween 20 (TBST). After washing the
membrane with TBST, the membrane was incubated with
pSTAT3(1:2000; CST), STAT3(1:1000;CST), DNMT1
(1:1000;CST), ACTIN(1:1000;CST), DNMT3a(1:1000;CST),
SOCS3(1:500;CST), CYCLIND1(1:1000;CST), BCL-
2(1:1000;CST), MMP-2(1:1000;CST), MMP-9 (1:1000;
CST) overnight at 4°C. Then, the membrane was washed
with TBST, and incubated with secondary antibodies di-
luted at 1:2000 for 1 h at room temperature. The
immuno-reactive protein bands were visualized using an
ECL kit. Immuno-reactive band intensities were quantified
using Image J software.
Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Total mRNA was extracted from pancreatic cancer cell
lines using TRIzol reagent. Then, CDNA was synthe-
sized from 1 μg of total RNA using oligo dT and Quant
Reverse Transcriptase (Tiangen, China). Real-time quan-
titative PCR was then conducted using SYBR Green
(Roche) according to the manufacturer’s instructions.
The primers used for SOCS3 and β-ACTIN are listed in
Table 1. PCR conditions were as follows: 94°C for 30 s,
60°C for 30 s and 72°C for 90 s, for 30 cycles, and a final
extension at 72°C for 5 min. Relative expression levels of
the genes were calculated using the 2-ΔΔCT method.
Cell transfection
Lentiviral pGMLV-SC6 RNAi vectors expressing short
hairpin RNA against human DNMT1 and GFP used as a
negative control were constructed. High-titer lentiviral
vector stock was produced in 293T cells using HG trans-
gene reagent-mediated cotransfection with pGMLV and
pUC19 packaging vectors. Freshly prepared viruses were
used to infect Bxpc3 cells with rich DNMT1 expression
and selected, maintained with 0.8 μg/ml puromycin.
DNMT1 expression vector or the corresponding empty
vector (Sino Biological Inc., China) were transiently trans-
fected into pancreatic cancer cells using X-tremeGENE
HP DNATransfection Reagent (Roche, China).
Human SOCS3-specific short interfering RNA (siRNA)
sequence and nonsense siRNA used as negative control
(NC) were synthesized (Genepharma, Shanghai, China)
(Table 1). Panc1 cells (2 × 105) were seeded into 6-well
plates and were grown until 60 %–80 % confluent. The
cells were transiently transfected with 20 nmol/L of
SOCS3 siRNA or NC siRNA using X-tremeGENE
siRNA Transfection Reagent (Roche, China) according
to the manufacturer’s instruction. After 48h, protein ex-
pression levels of SOCS3 were detected using Western
blotting. The SOCS3 coding sequences were amplified
and cloned into PGMLV-PA6 constructs; then, according
to the manufacturer’s instructions, the lentiviral expres-
sion constructs and a packaging plasmid mix were co-
transfected into HEK-293 T cells, viral particles were
collected and titers were determined. Finally, Bxpc3 cells
were transfected with the lentiviruses using Lipofecta-
mine 2000.
Table 1 PCR primers
Gene Sequence (5′-3′) Experimental use
SOCS3 CAGCTCCAAGAGCGAGTACCA (forward) Real-time PCR
AGAAGCCGCTCTCCTGCAG (reverse)
β-ACTIN GCACCACACCTTCTACAATGAGC (forward) Real-time PCR
TAGCACAGCCTGGATAGCAACG (reverse)
SOCS3(M) TGATTAAATATTATAAGAAGGTCGGTCG (forward) Methylation-specific PCR
ACTAACTACGTACGAAACCGAAACG (reverse)
SOCS3(U) GTAGTGATTAAATATTATAAGAAGGTTGGTTG (forward) Methylation-specific PCR
CTAACTACATACAAAACCAAAACAA (reverse)
SOCS3 siRNA-1 CCAAGAACCUGCGCAUCCAdTdT RNA interference
SOCS3 siRNA-2 GGACCAAGAACCUACGCAUdTdT RNA interference
SOCS3 siRNA-3 CCAAGAGAGCUUACUACAUdTdT RNA interference
SOCS3 siRNA-NC UUCUCCGAACGUGUCACGUTT RNA interference
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Methylation-specific PCR
The methylation status of the SOCS3 promoter region
near the recognized STAT3-SOCS3 binding sites (−1046
through −1038, TTCCAGGAA, the start codon ATG as
+1) [28–30] was determined by methylation-specific
PCR (MSP) using bisulfite-modified DNA. The se-
quences of the methylated and unmethylated primer
pairs are listed in Table 1 (methylated products: −1079
through −925, 155bp; unmethylated products: −1083
through −926, 158bp). DNA was modified using an EZ
DNA Methylation-GoldTM kit (ZYMO RESEARCH
CORP). Amplification was achieved in a 25μl reaction
volume containing 0.5μl of each primer, 2μl of modified
DNA, 12.5μl 2 × Tag Enzyme (DBI, China). The PCR re-
action conditions were as follows: heating at 95°C for 10
min, 35 cycles consisted of denaturation at 94°C for 15
s, annealing at 55°C for 30 s, extension at 72°C for 30 s,
then a final 10-min extension at 72°C. The PCR prod-
ucts were visualized on a 2 % agarose gel using DuRed
and UV illumination. Sss-I methylase-treated DNA (Qia-
gen) and unmethylated and bisulfite converted human
control DNA were used as positive and negative con-
trols, respectively.
Co-immunoprecipitation
Total protein of cells in a 10 cm dish was lysed in 1 ml
ice cold lysis buffer (RIPA). Equal aliquots (approxi-
mately 0.475 ml of each) were incubated at 4°C over-
night with either 1μg rabbit anti-pSTAT3 (CST) or 1μg
purified rabbit IgG (Sigma) as a control, then added to
30μl of Protein A + G Agarose (Pierce) shaken at 4°C for
4 h, and then centrifuged at 2500 g for 5 min, carefully
sucked out supernatant. The precipitation was washed
five times with lysis buffer, re-suspended in SDS buffer,
and primary antibodies against pSTAT3 and DNMT1
were used for western blot analyses.
Luciferase reporter assay
The human SOCS3 promoter region (−1084 through
+1) including the STAT3-SOCS3 binding sites was amp-
lified using PCR and inserted into pGL3 vector
(Promega). The PCR primers were as follows: 5′
CCTTAAGCTAGC AGTAGTGACTAAACATTACA 3′
(forward, NheI), 5′ CCTTAAAGATCT GGCGCACG-
GAGCCAGC 3′ (reverse, BgIII) [31]. Panc1 cells (5 ×
104) were seeded on 24-well plates 1 day before transfec-
tion. The cells were transfected with 0.45μg reporter
plasmid (pGL3-SOCS3) or DNMT1 plasmid at the same
time using Lipofectamine 2000 transfection reagent.
0.05μg Renilla luciferase plasmid phRL-tk was co-
transfected to normalize the transfection efficiency.
Then, 24 h after the transfection, the cells were treated
with 100 ng/ml IL-6 or 5μmol/L 5-AZA. Luciferase ac-
tivity was measured 48 h after treatment using the Dual
Luciferase Reporter Assay System (Promega). All of the
assays were performed in triplicate.
Flow cytometry
Pancreatic cancer cells that had been overexpressed or
siRNA knocked down SOCS3 were trypsinized, washed
in phosphate-buffered saline, and fixed in ice-cold 70 %
ethanol-phosphate-buffered saline. After washing out
ethanol, the fixed cells were treated with 0.01 % RNase
for 10 min at 37°C and then stained with 0.05 % propi-
dium iodide for 20 min at 4°C in the dark. The cell cycle
distribution was determined using FACScan flow cytom-
etry. Cell apoptosis and necrosis were assessed using the
Annexin V-FITC apoptosis kit according to the manu-
facturer’s instructions.
Cell proliferation assay
The SOCS3 gene stably transfected Bxpc3 cells (1.0 ×
103/well) were plated in 96-well plates (three wells per
group) before measurement. Cell proliferation was ana-
lyzed using the CCK8 Cell Proliferation Assay Kit (Invi-
trogen, Carlsbad, California, USA). 10 μL of CCK8 was
added to each well and incubated for 2 h. The number
of viable cells was calculated by absorbance measure-
ments at 450 nm.
Wound healing assay
Cell migration was assessed using classical wound heal-
ing assays. Pancreatic cancer cells were seeded in six-
well plates and transfected when they were attached.
After transfection for 48 h, wounds were scratched on
the monolayer of cells using 20μl pipette tips and
washed twice to remove non-adherent cells. The images
(100×) of the same areas were recorded using a photo-
microscope at 0 h, 8 h and 24 h.
Transwell invasion assay
For the invasion assay, the upper chamber was precoated
with Matrigel (BD Bioscience) according to the manu-
facturer's protocols. Then, 48 h after transfection, the
cells were harvested, counted and suspended in serum-
free RPMI-1640 medium. Then, 1 × 105 Panc1 cells or
Bxpc3 cells in 100μl medium were added to the upper
chamber. Medium containing 10 % FBS was added to
the lower chamber as a chemoattractant. After 24h incu-
bation, chambers were fixed with 4 % paraformaldehyde
for 20 min, then 0.1 % crystal violet solution for 15 min,
and then immersed in PBS for 20 min. Finally, cells in
the lower chamber were counted under an inverted
microscope. The cell numbers in 5 random fields of view
were counted (100×).
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Tissue microarrays
A pancreatic cancer tissue microarray purchased from Xin
Chao (Shang Hai) was used for immunohistochemistry
analysis of SOCS3 expression. Pancreatic cancer and
matched pericancerous samples were collected between
2004 and 2009 from 90 patients with informed consent.
Ethical approval for the study was obtained from the ethical
committee of biobank centre-associated hospitals. Clinico-
pathological characteristics of the tissue microarray include
age, gender, tumor volume, survival time, pT, pN and
pTNM classification. The information is listed in Table 2.
In vivo tumorigenicity
All protocols for the animal studies were approved by
the institutional Animal Research Ethics Board. SOCS3
overexpressed Bxpc3 cells and controls (1 × 107 cells in
0.2 ml phosphate-buffered saline) were subcutaneously
injected into the dorsal flank of 5-week-old nude mice;
each group included 5 mice. Six weeks after injection of
the cells, mice were sacrificed and the volume and
weight of the tumors were recorded. The tumor volume
was determined using the following formula: tumor vol-
ume (mm3) = length (mm) × width (mm) 2/2.
Statistical analysis
The data are presented as the means ± standard devi-
ation (SD). Quantitative RT-PCR, CCK-8 assay, cell
apoptosis and cell cycle analysis, migration and invasion
assay, luciferase reporter assay and nude mice tumor for-
mation assay were assessed using one-way analysis of
variance (ANOVA) for factorial design. The association
between SOCS3 IHC expression and clinicopathological
parameters in pancreatic cancers was analysed using
Kruskal-Wallis rank sum test. The postoperative survival
rate was analyzed with Kaplan–Meier method and the
survival differences of patient subgroups were compared
by the log-rank test. Independent variables with a P
value <0.05 in the univariate analysis were entered into
the multivariate Cox regression model. P–values < 0.05
were considered statistically significant, and P–values <
0.01 were considered highly statistically significant.
Results
Expression of pSTAT3 and SOCS3 in PDAC and matched
pericancerous tissue
IL-6, pSTAT3, DNMT1, DNMT3a, and SOCS3 were
evaluated by immunohistochemistry in five pairs of
PDAC and pericancerous tissue. We showed the repre-
sentative images of one pair in Fig. 1a. Immunoreactivity
of pSTAT3 and DNMT1 was observed mainly in the cell
nuclei, whereas IL-6, DNMT3a and SOCS3 were located
mainly in the cytoplasm. Statistical analysis of the IHC
scores for the specimens demonstrated that expression
of IL-6, pSTAT3 and DNMT1 was significantly increased
Table 2 Association between SOCS3 expression and clinicopathological parameters in pancreatic cancers
Parameter No. of cases Negative Weak Moderate Mean Rank p value
Gender 0.425
Male 57 24 27 6 44.03
Female 33 9 23 1 48.05
Age 0.289
< 60 41 17 22 2 42.68
≥ 60 49 16 28 5 47.86
Tumor Volume(cm3) 0.037
≤ 50 57 16 36 5 49.35
> 50 33 17 14 2 38.85
pT stage 0.584
T1 5 1 3 1 55.9
T2 70 25 42 3 44.9
T3 15 7 5 3 44.83
pN stage 0.038
N0 51 14 32 5 49.9
N1 39 19 18 2 39.74
pTNM stage 0.001
I 40 6 29 5 55.84
IIA 9 5 3 1 38.61
IIB 41 22 18 1 36.93
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in tumor tissues, while SOCS3 expression was decreased
as compared to pericancerous tissues (Fig. 1b). These
data might suggest IL-6, pSTAT3, DNMT1 as oncogene
and SOCS3 as tumor-suppressor gene in PDAC. Protein
expression levels of pSTAT3, STAT3 and SOCS3 were
also examined in the five pairs of PDACs and their
matched pericancerous tissues using western blots. We
found that STAT3 was obviously activated in tumor tis-
sues, while SOCS3 protein expression was higher in
their matched noncancerous tissues (Fig. 1c, Additional
file 1: Figure S1A). To further determine the relationship
between SOCS3 and pSTAT3, a panel of 9 pancreatic
cancer cell lines were analyzed; we also observed highly
activated STAT3 and lower expression of SOCS3 in
most cell lines (Fig. 1d , Additional file 1: Figure S1B),
suggesting that SOCS3 expression might be negatively
correlated with that of pSTAT3 in PDAC.
IL-6/STAT3 signaling activation increased expression of
DNMT1 and negatively regulated SOCS3 expression
As noted above, SOCS3 was downregulated and STAT3
was activated in pancreatic cancers. We next used real-
time PCR and western blots to confirm the correlation
between STAT3 activity and SOCS3 expression in pan-
creatic cancer cell lines. According to our studies, Aspc1
and Panc1 cells had relatively lower expression of
pSTAT3 while Bxpc3 and Capan2 cells had relatively
higher expression of pSTAT3. We thus selected them as
our cell models. IL-6 and S31-201 are agonist and in-
hibitor of the IL-6/Jak-2/STAT3 signaling pathway, re-
spectively. Panc1 cell proliferation increased by
treatment with IL-6 and Bxpc3 cell proliferation was
inhibited by treatment with S31-201 (Additional file 1:
Figure S1C). As shown in Figs. 2a and b, IL-6 treatment
reduced SOCS3 levels and activated STAT3 in Aspc1
Fig. 1 Expression of pSTAT3 and SOCS3 in PDAC and matched pericancerous tissue. a The representative images of immunohistochemistry
staining of IL-6, pSTAT3, DNMT1, DNMT3a and SOCS3 in one matched PDAC (T) and pericancerous tissue (P) (20 × objective). b Statistical analysis
of the IHC scores for the expression of IL-6, pSTAT3, DNMT1, DNMT3a and SOCS3 in the five pairs of PDAC and pericancerous tissue. c Protein
expression levels of pSTAT3, STAT3 and SOCS3 were examined in five pairs of PDACs (T) and their matched pericancerous tissues (P) using western
blots. d Protein expression levels of pSTAT3, STAT3 and SOCS3 were analyzed in nine pancreatic cancer cell lines using western blots
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and Panc1 cells. Conversely, S3I-201 treatment in Bxpc3
and Capan2 cells increased SOCS3 mRNA and protein
levels. This phenomenon revealed that SOCS3 expres-
sion was negatively regulated by pSTAT3. However,
SOCS3 was conventionally induced by IL-6 signaling
[32–35]. Because previous studies found that IL-6 could
induce DNMT1 expression, we took the methylation
modification of the SOCS3 gene into consideration. To
study whether IL-6 could induce DNA hypermethylation
in PDAC, we evaluated the expression of two represen-
tative DNMTs, DNMT1 and DNMT3a, in Aspc1and
Panc1 cell lines with IL-6 stimulation. Substantial in-
creases in pSTAT3 and DNMT1 expression were ob-
served in both cells but DNMT3A expression was not
substantially increased. Therefore, the results suggest
that IL-6 increased DNA methylation mainly through
up-regulation of DNMT1. We further found that S3I-
201 treatment could decrease the level of DNMT1 ex-
pression, but not DNMT3A expression, in Bxpc3 and
Capan2 cell lines (Fig. 2c). These data indicate that in
pancreatic cancer cells, IL-6 upregulated DNMT1 by ac-
tivating the IL-6/STAT3 signaling pathway.
STAT3 represses SOCS3 expression through recruitment
of DNMT1 in pancreatic cancer
Because we found that IL-6 could upregulate DNMT1
while downregulate SOCS3 levels in pancreatic cancer
cell lines, we further analyzed the possible correlation
between IL-6 induced DNMT1 expression and methyla-
tion modification of SOCS3. We used MSP to analyze
the methylation status of the promoter regions of
SOCS3 near the recognized STAT3-SOCS3 binding sites
Fig. 2 IL-6/STAT3 signaling activation increased expression of DNMT1 and negatively regulated SOCS3 expression. a Protein expression levels of
pSTAT3 and SOCS3 were analyzed in Aspc1 and Panc1 cells after IL-6 (100 ng/ml) and Bxpc3 and Capan2 cells after S31-201 (a STAT3 inhibitor,
10μM) treatment for 24 h using western blots. b mRNA expression levels of SOCS3 were analyzed in Aspc1 and Panc1 cells after IL-6 (100 ng/ml)
and Bxpc3 and Capan2 cells after S31-201 (a STAT3 inhibitor, 10μM) treatment for 24 h using quantitative real-time PCR. Results were expressed
as SOCS3/ACTIN. Gene expression measurements were performed in triplicate. Bars represented the mean ± SD. * p < 0.05, ** p < 0.01. c Protein
expression levels of pSTAT3, STAT3, DNMT1 and DNMT3a were analyzed in Aspc1 and Panc1 cells after IL-6 (100 ng/ml) and Bxpc3 and Capan2
cells after S31-201 (a STAT3 inhibitor, 10μM) treatment for 24 h using western blots
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in pancreatic cancer cell lines. The structure of SOCS3
and the location of the CpG islands are shown in Fig. 3a.
We found a negative correlation between promoter
methylation and basal SOCS3 protein levels shown in
Fig. 1 (Fig. 3b). As shown in Fig. 3c, the methylation
level of SOCS3 gene in Aspc1 and Panc1 cells increased
after IL-6 incubation for 24 h. In contrast, STAT3 inhibi-
tor (S3I-201) treatment for 24 h could eliminate the
methylation level of the SOCS3 gene in Bxpc3 and
Capan2 cells. Thus, we could conclude that IL-6/STAT3
signaling might influence the methylation level of the
SOCS3 gene.
In order to confirm our postulation, we further si-
lenced DNMT1 and analyzed SOCS3 expression in the
presence of IL-6. We found that SOCS3 expression was
dramatically increased and could be enhanced by IL-6
treatment in Bxpc3 cells with shRNA knockdown of
DNMT1 (Fig. 3d). To further confirm that SOCS3 ex-
pression loss was caused by promoter methylation, we
incubated Bxpc3 cells with 5-AZA, an inhibitor of DNA
Fig. 3 STAT3 represses SOCS3 expression through recruitment of DNMT1 in pancreatic cancer. a Structure of the SOCS3 gene. Bottom line is a
genomic sequence of SOCS3 gene containing Exon 1, Intron 1, and Exon 2. The translation start site ATG is defined as +1. The grey vertical bar
represents the recognized STAT3-SOCS3 binding site (−1046 through −1038). The arrows indicate primers used for MSP. b The SOCS3 gene
promoter methylation status was analyzed in four pancreatic cancer cell lines using MSP. M and U, PCR products of methylated and unmethylated
alleles, 155bp and 158bp, respectively; Con(M), methylation positive control; Con(U), positive control for unmethylation. c The SOCS3 gene promoter
methylation status was analyzed in Aspc1 and Panc1 cells after IL-6 (100 ng/ml) and Bxpc3 and Capan2 cells after S31-201 (a STAT3 inhibitor, 10μM)
treatment for 24 h using MSP. d Bxpc3 cells were infected with lentiviral vectors carrying control vector (EV) or DNMT1-specific shRNAs (shDNMT1),
then followed by puromycin selection. Protein expression levels of DNMT1 and SOCS3 were analyzed in Bxpc3/EV and Bxpc3/shDNMT1 cells in the
absence or presence of IL-6 (100 ng/ml) for 24 h. e Protein expression levels of SOCS3 were analyzed in Bxpc3 cells after 5-Aza (5μM) treatment for 72
h (with medium changed every day). Protein expression levels of SOCS3 were also analyzed in Panc1 cells which were cultured in the presence of IL-6
(100 ng/ml) or 5-Aza (5μM) 72 h (with medium changed every day) using western blots. f Panc1 cells were co-transfected with the indicated plasmids
(reporter plasmid EV alone or DNMT1 plasmid simultaneously). Then, 24 h after the transfection, the cells were treated with IL-6 (100 ng/ml) or 5-AZA
(5μM) for 48 h, and the luciferase activity was measured. g Lysates of Bxpc3 cells were subjected to immunoprecipitation with rabbit IgG or pSTAT3
antibody, and then followed by western blot to detect the interaction of phosphorylated STAT3 with DNMT1. The effect of IL-6 on the interaction
between phosphorylated STAT3 and DNMT1 in Panc1 cells were also analysed using western blots. * represents the location of DNMT1 (183 kd)
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methylation and this treatment could significantly upreg-
ulate SOCS3 expression. Similar western blot analyses
showed that in the presence of 5-AZA, IL-6 mediated
down-regulation of SOCS3 in Panc1 cells was reversed
(Fig. 3e). In conclusion, these data suggest that the IL-6/
STAT3 signaling pathway downregulated SOCS3 expres-
sion by inducing DNMT1 mediated gene methylation.
To observe the effect of pSTAT3 and DNMT1 on
SOCS3 promoter activity, we next transfected Panc1
cells with a reporter vector encoding Luciferase under
control of the SOCS3 promoter (PGL3-SOCS3). Concur-
rent IL-6 treatment or DNMT1 plasmid transfection
with the SOCS3 reporter construct decreased SOCS3
promoter activity. Nevertheless, IL-6 and 5-AZA treat-
ment simultaneously could abolish pSTAT3-mediated
repression of SOCS3 transcription (Fig. 3f ). We could
conclude from the above results that there must be some
association among activated STAT3, DNMT1 and
SOCS3. Therefore, we examined whether STAT3 could
form complexes with DNMT1 in pancreatic cancer cells
using co-immunoprecipitation assay.
We observed that endogenous pSTAT3 did interact
with DNMT1 in Bxpc3 cells and IL-6 treatment en-
hanced the interaction in Panc1 cells (Fig. 3g). So we
considered that pSTAT3 repressed SOCS3 expression
through increasing DNMT1 expression and recruiting
DNMT1 to the promoter region of SOCS3 in pancreatic
cancer according to our studies.
SOCS3 induces pancreatic cancer cell apoptosis and cell
cycle arrest
Our results suggest a probable mechanism of decreased
expression of SOCS3 in PDAC. To further elucidate the
role of SOCS3 during pancreatic cancer development,
we selected Bxpc3 and Panc1 cells which had relatively
low and high expression of SOCS3 as our cell models.
Protein level of SOCS3 was effectively enhanced after
transfection with expression vector in Bxpc3, and
SOCS3 knockdown in Panc1 was efficient after transfec-
tion with siSOCS3 1# compared to siNC. (Fig. 4a). The
CCK8 assay showed that overexpression of SOCS3 could
remarkably inhibit Bxpc3 cell growth (Fig. 4b). We next
examined cell cycle and apoptosis using flow cytometry.
Analysis of apoptosis using Annexin V and PI staining
revealed that overexpression of SOCS3 increased apop-
tosis, whereas silencing SOCS3 decreased apoptosis
(Fig. 4c, e). Cell cycle was blocked mainly at the G1-S
transition by SOCS3 according to our studies (Fig. 4d,
e). Consistent with these results, the western blot data
showed that cell cycle-related protein CYCLIND1 and
anti-apoptotic protein BCL-2 were downregulated in
Bxpc3/SOCS3 OE cells, and upregulated in Panc1/
siSOCS3 cells (Fig. 4f ). The results shown in Fig. 4f also
suggest that downregulation of SOCS3 effectively
enhanced the expression level of activated pSTAT3 and
its downstream target genes CYCLIND1 and BCL-2.
SOCS3 inhibits migration and invasion of pancreatic
cancer cells in vitro
To further evaluate the role of SOCS3 in the metastasis
of pancreatic cancer cells, we used wound healing and
transwell invasion assays. The results showed that within
24 h, Panc1 cells transfected with siRNA against SOCS3
occupied approximately 77 % of the wound, while Panc1
cells with control siRNA covered approximately 64 % of
the wound, indicating that knockdown of SOCS3 pro-
moted the migration of Panc1 cells. Similarly, transwell
assays showed that more Panc1 cells migrated through
the matrix gel when SOCS3 expression was inhibited
(Fig. 5a, b, c). A gain-of-function assay was also con-
ducted by transfecting SOCS3 cDNA plasmid into Bxpc3
cells. As expected, overexpression of SOCS3 suppressed
the migration and invasion capability of Bxpc3 cells
(Fig. 5a, b, c). And we performed western blotting on in-
vasion related proteins. The results showed a notably el-
evated protein level of MMP-2 and MMP-9 for Panc1/
siSOCS3 cells as compared with control cells (Fig. 5d).
Conversely, the expression levels of MMP-2 and MMP-9
were reduced in Bxpc3/SOCS3 OE cells. Taken together,
these results softened our statement regarding the inhib-
ition of SOCS3 in migration and invasion of pancreatic
cancer cells.
Overexpression of SOCS3 suppresses tumor formation in
vivo
To determine whether SOCS3 was involved in pancre-
atic cancer tumourigenesis, equal numbers (1 × 107) of
Bxpc3 cells transfected with stable SOCS3 gene overex-
pression or control vector were subcutaneously injected
into nude mice. Six weeks after injection of the cells,
mice were sacrificed and the volume and weight of the
tumors were recorded. As shown in Fig. 6a and b, the
overexpression of SOCS3 decreased the size and weight
of the xenograft local tumor compared with control vec-
tor groups.
Association between SOCS3 expression and
clinicopathological parameters in PDAC
A tissue microarray that included pancreatic cancers (n
= 90) and matched pericancerous tissues was used for
the immunohistochemistry analysis of SOCS3 protein
expression.
Figure 6c shows representative positive and negative
staining images of SOCS3. We found that nearly 80 % of
the pericancerous tissues had positive SOCS3 staining
(16.7 % with moderate staining and 63.3 % with weak
staining), whereas only 63.3 % of the tumors had positive
SOCS3 staining (7.8 % with moderate staining and
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55.5 % with weak staining) (Fig. 6d). The difference in
SOCS3 protein expression between pericancerous and
cancer tissues was statistically significant (p = 0.005).
The association of SOCS3 expression with the clinico-
pathological variables of pancreatic cancer patients was
shown in Table 2. Low SOCS3 expression was associated
with larger tumor volume (p = 0.037), lymph node me-
tastasis (p = 0.038) and advanced TNM stage (p = 0.001),
but not with other clinical parameters. The median sur-
vival after operation was 24 and 42 months for negative
and positive SOCS3 expression, respectively. Kaplan-
Meier survival curve showed that the overall survival
rate was significantly lower in patients with negative
SOCS3 expression (Fig. 6e). Furthermore, multivariate
analysis through the Cox proportional hazard model was
conducted to determine the independent prognostic
Fig. 4 SOCS3 induces pancreatic cancer cell apoptosis and cell cycle inhibition. a Protein level of SOCS3 was effectively enhanced after transfection
with expression vector in Bxpc3, and SOCS3 knockdown in Panc1 was efficient after transfection with siSOCS3 1# compared to siNC. b The CCK8 assay
was used to examine cell growth of SOCS3 gene stably transfected Bxpc3 cells and a reduction of absorbance was observed at 24 h, 48 h and 72 h
(P < 0.01). c Panc1 and Bxpc3 cells were transiently transfected with SOCS3 siRNA and SOCS3 expression vector, respectively. Cell apoptosis was
measured using the flow cytometry 48 h post transfection. d The cell cycle distribution of SOCS3-modulated Panc1 and Bxpc3 cells was analyzed using
the flow cytometry. e The proportions of apoptosis cells and cells in different phases of cell cycle were quantified. Data represents three independent
experiments in triplicate. f Protein expression levels of cell apoptosis and cell cycle related genes were analyzed in Bxpc3 and Panc1 cells 48 h after
transfection using western blots
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factor. We observed that low expression of SOCS3 and
pN1 in tumors was associated with a poor prognosis in-
dependent of other clinical covariates, and the pTNM
stage I was associated with a better prognosis compared
to pTNM stage IIB (Table 3).
Discussion
A link between chronic inflammation and cancer risk has
been established [36, 37]. The IL-6/STAT3 signaling axis
is recognized as a mechanistic link between the inflamma-
tory tumor microenvironment and pancreatic cancer [38,
39], which promotes tumor initiation and progression not
only through the regulation of oncogenes [40], but also by
epigenetic modification of tumor suppressor genes [41].
However, the mechanism of the persistent aberrant ac-
tivation of this signaling pathway in PDAC remains un-
clear. In the present study, we found for the first time
that IL-6/STAT3- mediated SOCS3 gene methylation via
DNMT1 may account for the imbalance of this signaling
pathway. We also identified SOCS3 as a tumor suppres-
sor gene important for pancreatic tumor growth and
metastasis.
As a key negative feedback regulator of the IL-6/
STAT3 signaling pathway, SOCS3 expression is usually
induced upon IL-6 stimulation via Janus kinas 2 (JAK-2)
/STAT3 under physiological conditions [15, 42]. In con-
trast, we demonstrated that SOCS3 expression was
down-regulated in PDAC tissues while pSTAT3
Fig. 5 SOCS3 inhibits migration and invasion of pancreatic cancer cells in vitro. a The wound healing migration assays were carried out in Panc1
cells after transfection with siSOCS3 as well as Bxpc3 cells after transfection with overexpression vector of SOCS3. Microscopic observations were
recorded at 0, 8 and 24 h after scratching the cell surface (100×). Representative images from every independent experiment were shown. b Transwell
invasion assay with matragel were performed in Panc1/siSOCS3 and Bxpc3/ SOCS3 OE cells (100×). c Quantitative analysis of the wound closure rates
and invasion cells. The percentage of the wound healing was calculated as (the width of wound at 0 h - the width of wound at 24 h)/ the width of
wound at 0 h. All experiments were carried out in triplicate. d Protein expression levels of MMP-2 and MMP-9 were analyzed in Bxpc3 and Panc1 cells
48 h after transfection using western blots
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expression was up-regulated. And SOCS3 induction was
decreased in response to IL-6 in pancreatic cancer cells
in our study. To illustrate the contradiction, the epigen-
etic modification was taken into consideration. Some in-
flammatory factors were reported to change the
methylation status of the SOCS3 promoter and further
inhibit SOCS3 expression [43, 44], but the mechanisms
were not clear enough. We showed that DNMT1 other
than DNMT3a, a conventional DNA methylation in-
ducer, could be upregulated by IL-6/STAT3 signaling.
This finding is in agreement with previous reports [45–
47]. It was also reported that SOCS3 expression in ul-
cerative colitis-related colorectal cancer was effectively
regulated by IL-6 via DNMT1 [48]. Our study further
showed that demethylation treatment or DNMT1
knocked down could reverse IL-6 mediated down-
regulation of SOCS3 in pancreatic cancer cells. There-
fore, we proposed that SOCS3 epigenetic silence was
due to IL-6/STAT3 signaling pathway induced methyla-
tion via increased DNMT1.
Although pSTAT3 seems to act mainly as a transcrip-
tion activator, transcriptional repression by pSTAT3
Fig. 6 Nude mice tumor formation assay and the expression of SOCS3 in the tissue microarray. a Images of xenograft tumors in nude mice
formed by SOCS3 gene stably transfected Bxpc3 cells and the controls. b Tumor volume and weight of xenograft tumors in nude mice were
quantitatively evaluated. c Represenative staining patterns of negative IHC staining of SOCS3 in pancreatic cancer tissue sample (T1) while moderate
staining in matched pericancerous tissue (P1) in the tissue microarray. The image P2 was classified as weak staining of SOCS3 in the pericancerous
tissue. d Quantification of SOCS3 IHC staining in the pancreatic cancer tissue microarray (The difference between pancreatic cancer and pericancerous
tissues is significant, P = 0.005). e Kaplan-Meier survival method and log-rank test were used to evaluate overall survival and compare the differences
between the two groups based on the SOCS3 status, P = 0.034
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through interacting with NF-κB [43], c-jun [49], HDAC1
[50] and DNMT1 [51] has also been described. This re-
port provides the evidence that oncogenic STAT3
promotes epigenetic gene silencing in synergy with
DNMT1. Binding of pSTAT3 to a gene promoter, as
demonstrated here for SOCS3, could be the step that
provides an anchor for DNMT1 that directly mediates
DNA methylation in pancreatic cancer.
There have been varying findings concerning the roles
of SOCS3 in tumourigenesis and tumor progression. The
association of SOCS3 expression with the biological be-
havior of pancreatic cancer cells and clinico-pathological
features in human PDAC has not been investigated. Our
study first demonstrated that SOCS3 expression was
down-regulated in PDAC tissues and overexpression of
SOCS3 decreased the proliferation and invasion potential
of pancreatic cancer cells both in vivo and vitro. Further-
more, in our microarray analysis, we found that low ex-
pression of SOCS3 was a significant predictor for larger
tumor volume, lymph node metastasis, advanced TNM
stage and even poorer overall survival in PDAC patients.
This is similar to the role of SOCS3 in lymphoma [52],
prostate cancer [53] and hepatocellular cancer [54].
Therefore, we conclude that SOCS3 is a candidate tumor
suppressor-gene of PDAC.
The limitation of the study is the up-regulation of
pSTAT3 or down-regulation of SOCS3 is not an univer-
sal feature of various cancer cell lines, which might re-
sult from the heterogeneity of different cancer cell lines.
Besides, cell biological behavior depends on multiple sig-
naling pathways. For Aspc1 and Panc1 cells, although
the STAT3 signaling pathway might not be the main
pathway which plays a decisive role in their biological
behavior in vitro, they are greatly influenced by the in-
flammatory microenvironment in vivo. In the present
study, we treated Aspc1 and Panc1 cells which had en-
dogenous relatively low expression of pSTAT3 with IL-6
in vitro, to partially recapitulate the inflammatory micro-
environments in vivo. Their malignant biological behav-
iors enhanced, as previously reported when IL-6/STAT3
signaling is activated [55, 56]. Although SOCS3 levels in
Aspc1 and Panc1 cells are relatively high compared to
others in vitro, we found a significantly reduced expres-
sion of SOCS3 after treatment with IL-6.
Table 3 Univariate and multivariate analysis of different prognostic parameters in 90 pancreatic cancer patients after
pancreaticoduodenectomy
Parameters Category No. Univariate Multivariate















N0 51 43.1 1
N1 39 23.1 6.539 (1.266 to 33.764) 0.025
pTNM stage 0.033
I 40 47.5 0.079 (0.015 to 0.423) 0.003
IIA 9 33.3
IIB 41 22 1
SOCS3 expression 0.034
negative 33 24.2 1.815 (1.037 to 3.179) 0.037
positive 57 40.4 1
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Another discrepancy is the inconsistency between the
expression level of SOCS3 protein and the differentiated
degree of pancreatic cancer cell lines. As reported in nu-
merous publications, cancer progression is a multistep
process that requires involvement of several biological
mechanisms and sequential acquisition of multiple gen-
etic lesions. Therefore, we presume that SOCS3 may co-
operate with other genes to ultimately determine cancer
biological behaviors. This would explain why there might
be a fraction of tumors positive to SOCS3 but with
poorly differentiated characteristics (i.e.Panc1 cells).
What is clear from our data is that Panc1 cells acquire
more aggressive features when SOCS3 is knocked down,
which is in accordance with other previously published
studies. Moreover, we provide evidences that cell prolif-
eration and invasion related proteins change, which
highlight again a relevant role of SOCS3 in tumor ag-
gressiveness. Nevertheless, further study about this issue
needs to be done in our future work.
Conclusions
In summary, our results indicate that activated IL-6/
STAT3 signaling could induce SOCS3 methylation via
DNMT1 in pancreatic cancers, which may account for
the imbalance of the signalling pathway. We also identify
SOCS3 as a tumour suppressor gene important for pan-
creatic tumour growth and metastasis. Ultimately, these
data suggests that various inhibitors of STAT3 or
DNMT1 may become novel strategies for treating pan-
creatic cancer.
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